Furthermore, combination treatment between CEA-CAR-T cells in addition to recombinant human interleukin 12 (rh-IL12) in mouce models show effective and elevated anti-tumor activity of CAR-T cells among various types of solid tumors including CRC (151). This evidence concerns the gene CEACAM5 and colorectal carcinoma.